Zobrazeno 1 - 10
of 21
pro vyhledávání: '"R M, Orr"'
Autor:
C. F. J. Barnard, J. F. Vollano, Kenneth R. Harrap, R. M. Orr, Barry A. Murrer, M. C. Nicolson, C. F. O'neill, Giandomenico Christen M
Publikováno v:
British Journal of Cancer
Seventeen alkylamine ammine dicarboxylatodichloroplatinum(IV) complexes of general structure c,t,c-[PtCl2(OCOR1)2NH3(RNH2)], where R = aliphatic or alicyclic and R1 = aliphatic or aromatic, have been evaluated against L1210 cell lines with acquired r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16aec41a4118b068938ddb7a3befab69
https://doi.org/10.1038/bjc.1994.320
https://doi.org/10.1038/bjc.1994.320
Publikováno v:
British Journal of Cancer
Cell killing of L1210 cells by cisplatin has been studied using flow cytometry and DNA gel electrophoresis. Ten hours after a supralethal dose of drug (100 microM), extensive apoptosis was induced. Cells were also susceptible to the induction of apop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ee79d4664fa7cb8522a2563f5587b18
https://doi.org/10.1038/bjc.1994.14
https://doi.org/10.1038/bjc.1994.14
Autor:
Lirong Wang, Joshua Kim, Vineeth Abraham, Rania H. Abd El-Maksoud, Yullin Kim, R. John Koshel, Ryan G. Irvin, Brian C. Primeau, R. M. Orr, Amber Czajkowski, Karlton Crabtree, Takeshi Nakazawa, Soha Namnabat, Martha Dawsey, Erich de Leon, Scott Richardson, Ron Liu, Michael W. Kudenov
Publikováno v:
SPIE Proceedings.
This past spring a new for-credit course on illumination engineering was offered at the College of Optical Sciences at The University of Arizona. This course was project based such that the students could take a concept to conclusion. The main goal o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3cebd685219c2f2c0bfeeb61ee5e9576
https://doi.org/10.1117/12.828806
https://doi.org/10.1117/12.828806
Autor:
R M, Orr, B P, Monia
Publikováno v:
IDrugs : the investigational drugs journal. 1(2)
Antisense molecules have the potential to halt a wide variety of diseases through inhibition of target gene expression. Five antisense phosphorothioates are currently in clinical studies for cancer therapy and encouraging early data have been present
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::69d3f0c7e68a83a263e59fa1d0e51746
https://pubmed.ncbi.nlm.nih.gov/18465532
https://pubmed.ncbi.nlm.nih.gov/18465532
Autor:
R M, Orr
Publikováno v:
Current opinion in investigational drugs (London, England : 2000). 2(10)
Loris Therapeutics (formerly GeneSense Therapeutics) is developing the antisense oligonucleotide GTI-2040, directed against the R2 component of ribonucleotide reductase, for the potential treatment of cancer [348194]. It is in phase I/II trials [3537
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6321ae6b121269be8514e3df553a73f1
https://pubmed.ncbi.nlm.nih.gov/11890366
https://pubmed.ncbi.nlm.nih.gov/11890366
Autor:
R M, Orr
Publikováno v:
Current opinion in molecular therapeutics. 1(3)
The University of Pennsylvania is developing an antisense oligonucleotide (AS ON) as a potential treatmentfor myelogenous leukemia. The 24-mer phosphorothioate (PS) ON targets the c-myb gene (codons 2 to 9), a regulator of transcription. In a pilot s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::96fcbcc8f6a9bcf4de7356762dcfd11b
https://pubmed.ncbi.nlm.nih.gov/11713805
https://pubmed.ncbi.nlm.nih.gov/11713805
Autor:
R M, Orr
Publikováno v:
Current opinion in molecular therapeutics. 3(3)
Fomivirsen (ISIS-2922, Vitravene) is an antisense 21 mer phosphorothioate oligonucleotide with sequence complementarity to the coding region of the major immediate-early gene of human cytomegalovirus (CMV). Developed by Isis Pharmaceuticals Inc, fomi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::719181c0ff812031a89c46b3f87ab291
https://pubmed.ncbi.nlm.nih.gov/11497353
https://pubmed.ncbi.nlm.nih.gov/11497353
Autor:
R M, Orr, C F, O'Neill
Publikováno v:
Current opinion in molecular therapeutics. 2(3)
Over 200 patents disclosing antisense sequences have been published in the last year. 30 Of these, in which a therapeutic application is claimed, have been reviewed in this article. We have classified these under the headings of antibacterial, antivi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f8bea25c6b5aedab0992df86d744f351
https://pubmed.ncbi.nlm.nih.gov/11249627
https://pubmed.ncbi.nlm.nih.gov/11249627
Autor:
R M, Orr
Publikováno v:
Current opinion in molecular therapeutics. 2(2)
Genetronics Inc has developed a MedPulser and a needle array applicator that delivers electric pulses to tumors and induces a transient permeabilization. Used in conjunction with intratumoral injections of anticancer drugs, this form of therapy, term
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b0d2963ece4b2e0a292e5f414e3cd685
https://pubmed.ncbi.nlm.nih.gov/11249643
https://pubmed.ncbi.nlm.nih.gov/11249643
Autor:
F I, Raynaud, R M, Orr, P M, Goddard, H A, Lacey, H, Lancashire, I R, Judson, T, Beck, B, Bryan, F E, Cotter
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 281(1)
An 18-mer full-phosphorothioate oligonucleotide with sequence antisense to the first six codons of the open reading frame of bcl-2 (G3139) has shown efficacy against the DoHH2 lymphoma implanted in severe combined immunodeficient mice. This study eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::36634859ce63422981aa504b1ea21ab1
https://pubmed.ncbi.nlm.nih.gov/9103525
https://pubmed.ncbi.nlm.nih.gov/9103525